Key Takeaways
- • Nourish secured $100 million in Series C funding led by Menlo Ventures, bringing total capitalization to $215 million and establishing the company as a major player in the metabolic health sector.
- • The round includes participation from nine institutional investors including Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak, and Operator Partners, reflecting broad institutional confidence in the dietitian-led care model.
- • Nourish operates as the country's largest dietitian-led metabolic health clinic with a network of 10,000+ Registered Dietitians paired with proprietary AI agents, delivering insurance-covered care available to over 200 million Americans across all 50 states.
- • Capital will fund expansion of Nourish's clinical network, AI agent development for patients and providers, scaling of its metabolic clinic care model, and deeper integration with health plans, employers, and health systems.
- • Menlo Ventures partner J.P. Sanday will join Nourish's board, providing strategic oversight as the company advances its AI-native virtual care platform designed to reverse chronic disease and address systemic healthcare inefficiencies.
Summary
Nourish, positioned as the country's largest dietitian-led metabolic health clinic, announced a $100 million Series C funding round that elevates the company's total raised capital to $215 million. The round was led by Menlo Ventures and draws support from a syndicate of nine additional institutional investors, including prominent venture and growth equity firms Thrive Capital, Index Ventures, J.P. Morgan Growth Equity Partners, Maverick Ventures, Y Combinator, BoxGroup, Atomico, Daybreak, and Operator Partners. The breadth of the investor base reflects substantial institutional appetite for Nourish's differentiated business model within the expanding metabolic health sector.
The company operates an AI-native virtual care platform that pairs its network of 10,000+ Registered Dietitians with proprietary AI agents to deliver personalized, insurance-covered metabolic health interventions. Nourish's care model integrates GLP-1 medication management, lab testing, and medical oversight into a unified platform designed to promote sustained behavioral change and reverse chronic disease. The company emphasizes accessibility, with partnerships across major health plans, health systems, and employers positioning Nourish's services as available to over 200 million Americans across all 50 states, typically at no patient cost through insurance coverage.
The capital deployment strategy focuses on four primary vectors: expansion of Nourish's clinical dietitian network, acceleration of AI agent development for both patient-facing and provider-facing applications, scaling of its metabolic clinic care delivery model, and deepening partnerships with institutional healthcare entities. Menlo Ventures' partner J.P. Sanday will assume a board seat, providing active strategic engagement as the company executes its growth mandate. This funding reflects investor conviction in both the secular tailwinds driving metabolic health demand and Nourish's operational execution in building a defensible, AI-augmented care delivery platform.
The company operates an AI-native virtual care platform that pairs its network of 10,000+ Registered Dietitians with proprietary AI agents to deliver personalized, insurance-covered metabolic health interventions. Nourish's care model integrates GLP-1 medication management, lab testing, and medical oversight into a unified platform designed to promote sustained behavioral change and reverse chronic disease. The company emphasizes accessibility, with partnerships across major health plans, health systems, and employers positioning Nourish's services as available to over 200 million Americans across all 50 states, typically at no patient cost through insurance coverage.
The capital deployment strategy focuses on four primary vectors: expansion of Nourish's clinical dietitian network, acceleration of AI agent development for both patient-facing and provider-facing applications, scaling of its metabolic clinic care delivery model, and deepening partnerships with institutional healthcare entities. Menlo Ventures' partner J.P. Sanday will assume a board seat, providing active strategic engagement as the company executes its growth mandate. This funding reflects investor conviction in both the secular tailwinds driving metabolic health demand and Nourish's operational execution in building a defensible, AI-augmented care delivery platform.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.